secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001104659-24-127487
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar pivots away from iopofosine I 131 accelerated approval; cuts workforce 60%
--------------------------------------------------------------------------------

- Due to FDA Type-C meeting, accelerated approval for iopofosine I 131 would now require randomized confirmatory study with PFS endpoint; company seeking strategic options for this program.
- Workforce cut ~60%; expects annual operating cost savings of ~$7.5M and ~$1.7M severance costs in Q4 2024/Q1 2025.
- Shifting focus to alpha- (CLR 121225) and Auger-emitter (CLR 121125) programs; expects to file IND applications in H1 2025 for Phase 1 solid tumor studies.
- Restructuring expected to extend cash runway into Q3 2025 from earlier depletion estimate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924127487/0001104659-24-127487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924127487/tm2430732d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-127487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer